New Oral Therapy Approved for Iron Deficiency in Adults
The FDA has approved Accrufer (ferric maltol; Shield Therapeutics) for the treatment of iron deficiency in adults.
All articles by Diana Ernst, RPh
Biosimilars Mvasi, Kanjinti Now Available in the US
Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.
ProVate Gets FDA Approval to Treat Pelvic Organ Prolapse
The FDA has approved ProVate (ConTIPI) for the temporary, nonsurgical management of pelvic organ prolapse in women.
Thiola EC Approved for Treatment of Cystinuria
A new enteric-coated formulation of Thiola has been approved by the Food and Drug Administration for the prevention of cystine stone formation.
Bavencio Plus Inlyta Approved as First-Line Tx for Advanced Renal Cell Carcinoma
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Gabapentin-Related CNS Side Effects in a Patient With ESRD
A recently published report describes the case of a 62-year-old patient who experienced rare but serious central nervous system (CNS) side effects following the initiation of gabapentin therapy.
Global Demand for Bladder Cancer Treatment Threatens Supply in 2019
TICE BCG is indicated for the treatment and prophylaxis of carcinoma in situ of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection.
SGLT2 Inhibitors and Urinary Tract Infections: What’s the Link?
For this study, the authors identified randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.
Fluoroquinolones Tied to Increased Risk for Arrhythmia, CV Mortality
To investigate the risk of cardiovascular adverse effects associated with this antibiotic class, researchers conducted a systematic review, meta-analysis, and network meta-analysis using studies identified through a search of MEDLINE, EMBASE, and the Cochrane Library.
Gardasil 9 Approved for Use in Women and Men 27 Through 45 Years Old
The approval of the expanded age range was based on data from a clinical trial which evaluated the efficacy of Gardasil (quadrivalent human papillomavirus recombinant vaccine) in 3253 women 27-45 years of age with a median duration of follow-up of 3.5 years post-dose 3.
- Loading...
Loading...
Next post in Men's Health Update
Loading... 
Loading...